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Edited by Ned ManteiAbstract Histone deacetylase inhibitors arrest the growth of
neuroblastoma cells and induce diﬀerentiation. Identiﬁcation of
target genes that co-ordinate andmediate these eﬀects is important
for understanding the function of this novel class of antitumour
drugs. We report here that trichostatin-A (TSA) speciﬁcally in-
duces the transcription ofCend1, a neuronal-lineage speciﬁc regu-
lator of cell cycle exit and diﬀerentiation, in neuroblastoma
Neuro2A cells, but not in non-neuronal cells. Furthermore, we
show that knockdown of Cend1 alleviates both the anti-prolifera-
tive and diﬀerentiation eﬀect of TSA. Our ﬁndings suggest that
Cend1 is an important molecular target for HDAC inhibition.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Epigenetic modiﬁcations of chromatin structure, including
histone acetylation/deacetylation, are implicated in prolifera-
tion versus diﬀerentiation decisions in mammalian cells, via
control of gene expression patterns. Accordingly, histone
deacetylase inhibitors (HDACIs) have been reported to arrest
cell cycle and induce diﬀerentiation [1,2]. These agents also in-
hibit the growth of cancer cells in animal models [3]. For exam-
ple, HDACIs suppress neuroblastoma tumor growth in human
and mouse neuroblastoma xenografts [4,5]. HDACIs have
antineoplastic eﬀects and several members of these therapeutic
molecules are already being evaluated in preclinical and clini-
cal trials [1,6,7]. This study was performed to identify novel
target genes for HDACIs and thus delineate the cellular path-
way(s) by which HDACIs arrest growth and induce diﬀerenti-
ation of neuroblastoma cells.
Trichostatin A (TSA) is a potent inhibitor of histone deacet-
ylases [2]. It inhibits growth and induces diﬀerentiation and
apoptosis of mouse neuroblastoma Neuro 2A (N2A) cells
[8–10]. We previously demonstrated that BM88/Cend1 is a neu-
ronal-lineage speciﬁc regulator that co-ordinates cell cycle with-
drawal and diﬀerentiation of neuronal progenitors [11–15].*Corresponding author. Present address: Center of Basic Research,
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doi:10.1016/j.febslet.2008.01.052Cend1 is characteristically expressed in neural stem/progenitor
cells in the central nervous system at a time window when these
are destined to generate neurons while it ceases to be expressed
when they give rise to glial cells [11,14]. In addition, Cend1 is ex-
pressed in young andmature neurons thus marking the diﬀerent
stages of the neuronal lineage. Most importantly, the eﬀect of
Cend1 overexpression on N2A cells shares similar aspects with
the eﬀect of TSA on these cells [8]. In particular, Cend1 overex-
pression in N2A is suﬃcient to inhibit proliferation and induce
the acquisition of a neuronal phenotype in the absence of exter-
nal stimuli, as judged by enhanced expression of neuronal
markers and neurite outgrowth-inducing signalling molecules
[12,13]. This eﬀect is achieved through activation of the
p53–p21–pRb signalling pathway that controls the balance be-
tween cell cycle progression and exit, cyclinD1 down-regulation
and cytoplasmic sequestration [13] and interference with the
Notch signalling pathway [15]. Conversely, Cend1 silencing
by means of siRNA interference yields an opposite phenotype
entailing increased proliferation and impairment of diﬀerentia-
tion [13,15]. Interestingly, although Cend1 expression is
restricted in vivo in neural cells where it is functionally involved
in the molecular cross-talk that controls cell cycle exit and
diﬀerentiation of neuronal progenitors [11–14], its anti-prolifer-
ative action is extended to non-neural cells. Transgene expres-
sion of Cend1 in NIH-3T3 ﬁbroblasts triggered cell cycle exit
but, apparently because of absence of the appropriate cellular
machinery required for neuronal diﬀerentiation, drove the cells
towards a pro-apoptotic pathway [13]. This observation raises
the possibility that Cend1 has a more generalized antitumour
action that may become of use in cancer therapeutics. Thus,
we sought to investigate whether Cend1 is a molecular target
for HDACIs. Indeed, here we report the involvement of Cend1
gene in mediating the anti-proliferative and diﬀerentiation-
inducing eﬀects of HDAC inhibition in neuroblastoma cells.2. Materials and methods
2.1. Cell culture and reagents
N2A, NIH-3T3 (ﬁbroblasts) and G774 (macrophages) cells were cul-
tured in Dulbeccos minimal essential medium containing 10% fetal
calf serum and antibiotics, and incubated at 37 C in 5% CO2. TSA
and Cycloheximide were from Sigma.
2.2. Transient transfections and reporter assays
Transient transfections and luciferase reporter assays were per-
formed with Lipofectamine (Invitrogen) and luciferase/b-galactosidase
kits (Promega), respectively, as previously described [16]. All experi-blished by Elsevier B.V. All rights reserved.
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ysis was performed by the paired two-sample Students t-test.
2.3. RNA extraction and real-time RT-PCR analysis
Total RNA was isolated by using the RNAeasy Kit (Qiagen) fol-
lowed by treatment with RQ1 DNase. Quantitative RT-PCR analysis
was performed as described [13].
2.4. siRNA in N2A
Knockdown of Cend1 and quantiﬁcation of proliferation, diﬀerenti-
ation and apoptosis in N2A were performed as previously described
[13]. Brieﬂy, for quantiﬁcation of cell indices 1000 cells were scored
from ﬁve independent experiments in each case.
2.5. Immunocytochemistry
Cend1 was detected using an aﬃnity puriﬁed polyclonal antibody
[12–15]. Anti-b-III-tubulin (Babco-Eurogenetech), anti-BrdU (Sigma),
anti-phosphorylated-H3 (Upstate), anti-p21 (Santa-Cruz), anti-p53
(Santa-Cruz), anti-actin (Santa-Cruz) and anti-activated-Caspase-3
(Santa-Cruz) antibodies were detected as previously described [13–
15]. Immunoﬂuorescent specimens were viewed and analyzed with a
Leica confocal microscope.3. Results
3.1. HDAC inhibition increases Cend1 mRNA and protein levels
in N2A cells
TSA is an inhibitor of HDAC activity in neuroblastoma N2A
cells [8–10]. It has also a cell cycle arrest and diﬀerentiation-
inducing eﬀect on these cells ([8] and Fig. 3E–F, I–J and 4A–
C). Similarly, Cend1 up-regulation is suﬃcient to decrease pro-
liferation and induce diﬀerentiation of N2A cells [12,13]. There-
by, to investigate the involvement of Cend1 in TSA-mediated
eﬀects on proliferation/diﬀerentiation of N2A cells, we ﬁrst
examined whether this HDACI aﬀects Cend1 gene expression.
TSA signiﬁcantly stimulates the expression of Cend1 mRNA,
both at 24 h and 48 h, as revealed by quantitative RT-PCR as-
says (Fig. 1A and B). Next, we asked whether the expression
of Cend1 protein could also be induced by the same treatments
in N2A. Our results demonstrate a signiﬁcant increase in Cend1
protein levels after TSA treatment, as shown by immunoﬂuores-
cence staining and Western blot analysis in N2A cells (Fig. 1C
and D). Quantiﬁcation of Cend1 protein levels relative to actin
using the ImageJ software showed that TSA induces Cend1 by
approximately 3-fold at 24 h and 4-fold (100 nM) or 5-fold
(300 nM)at 48 h, as comparedwith the untreated cells. Concom-
itant to Cend1 induction TSA is suﬃcient to induce p21, but
not p53, protein levels (Fig. 1E and Supplementary Fig. 1).
This is in agreement with the previously documented action of
TSA on p21 induction via a p53-independent pathway [17].
We then examined whether Cend1 up-regulation by TSA is
dependent on de novo protein synthesis. For this purpose, we
used cycloheximide (CHX), a protein synthesis inhibitor. Mea-
surement ofCend1mRNA levels by quantitative RT-PCR dem-
onstrated that TSA is not suﬃcient to induce this gene in the
presence of 40 lg/ml CHX (Fig. 1F), suggesting that the TSA-
mediated induction of Cend1 is dependent on de novo protein
synthesis. Collectively, these observations indicate that Cend1
may be an indirect target of HDAC enzymes in N2A cells.3.2. HDAC inhibition signiﬁcantly enhances Cend1 promoter
activity in N2A cells
We next investigated whether the Cend1 promoter could be
activated by HDAC inhibition. Transient transfection assayswere performed in N2A cells with three diﬀerent Cend1-lucif-
erase promoter constructs in the presence or absence of TSA
(Fig. 2A). We have previously shown that all three constructs
exhibit cell-type speciﬁcity restricting transcriptional activity to
neurons and cell-lines of neural origin [16]. N2A cells were
transiently transfected with Cend1-luciferase constructs and
treated with TSA or vehicle alone. We observed that
pGL(283/+63), pGL(82/+6) and pGL(82/+63) constructs
could be activated by TSA, 3, 4.2 and 7.8-fold, respectively
(Fig. 2B–D). These data suggest that the Cend1 promoter is
responsive to HDAC inhibition and that the TSA-mediated
induction of Cend1 gene expression is regulated at the tran-
scriptional level.
We have previously shown that Cend1 promoter activity is
Sp1-dependent and that Sp1 recognizes and binds to 4
DNA-response-elements present on the Cend1 promoter [16].
We therefore sought to test if Sp1 binding sites are also in-
volved in the TSA-mediated Cend1 induction. To this end, a
pGL(82/+63) construct that bears mutations in all 4 Sp1
binding sites, was transiently transfected in N2A cells in paral-
lel with the parental construct with intact Sp1 sites. The Sp1-
mutated construct showed a dramatic suppression of Cend1
promoter activity in the absence of TSA (Fig. 2D), as previ-
ously described [16]. Moreover, treatment with TSA was not
suﬃcient to induce transcriptional activity at the levels of the
parental pGL(82/+63) vector (Fig. 2D), suggesting an
involvement of Sp1 binding sites in the TSA-mediated tran-
scriptional induction of Cend1. Consistently, various HDACs
have been shown to interact with Sp1 being thus recruited
on the promoter region of genes containing Sp1-binding sites
to suppress their transcription [18,19]. Although such a role
for Sp1 in suppression of Cend1 transcription in N2A via
recruitment of an HDAC is possible, the observation that
the TSA-mediated induction of Cend1 is dependent on de novo
protein synthesis, also suggests operation of an indirect mech-
anism of action.3.3. HDAC inhibition is not suﬃcient to de-repress the Cend1
transcriptional activity in non-neuronal cell lines
We have previously shown that endogenous mammalian and
chick Cend1 is speciﬁcally expressed in the neuronal lineage
[11,14,16]. Thereby, we sought to investigate whether HDAC-
dependent repression of Cend1 gene participates in the suppres-
sion of this gene in non-neuronal cell lines. For this purpose we
determined Cend1mRNA levels in two non-neuronal cell lines:
NIH-3T3 and G774, at 24 and 48 h after treatment with either
100 nM or 300 nM TSA. Cend1 transcription remains inactive
in NIH-3T3 and G774 cell lines after TSA treatment (Fig. 2E–
G), suggesting that HDAC inhibition is not suﬃcient to de-re-
press the transcriptional activity of Cend1 in non-neuronal
cells. Moreover, TSA was not able to de-repress the Cend1 pro-
moter-driven luciferase activity in NIH-3T3 cells (data not
shown), further suggesting that HDAC inhibition is not suﬃ-
cient to de-repress Cend1 transcription in non-neuronal cell
lines.3.4. Cend1 knockdown alleviates the anti-proliferative,
diﬀerentiation-inducing eﬀect of HDAC inhibition in N2A
cells
To test whether Cend1 induction by TSA is involved in
mediating the anti-proliferative, diﬀerentiation-inducing eﬀects
Fig. 1. TSA-induced up-regulation of Cend1 gene expression in N2A cells requires de novo protein synthesis. (A and B) Total RNA was extracted
from N2A following exposure to 100 and 300 nM TSA for 24 h or 48 h. mRNA was examined by RT-PCR for Cend1 relative to Gapdh. (C) N2A
cells were immunostained for Cend1 after TSA treatment as indicated. (D) Protein extracts from N2A treated with TSA were analyzed with western
blot for Cend1 relative to actin. (E) Protein extracts from N2A treated with TSA as indicated, were analyzed with western blot for p21 and p53
relative to actin. Arrowhead indicates a non-speciﬁc band (F) Cend1 mRNA levels were quantiﬁed by RT-PCR following exposure to CHX in the
presence or absence of 100 nM TSA for 24 h. *P < 0.01, **P < 0.001, n.s. (not signiﬁcant, P > 0.1). Bar: 160 lm.
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down experiments (Fig. 3A). We used a previously tested siR-
NA molecule (siCend1) that targets and eﬃciently down-
regulates Cend1 [13,15]. siCend1 is suﬃcient to eﬀectively
block the TSA-mediated induction of Cend1 transcript and
protein levels (Fig. 3B–D).
We ﬁrst veriﬁed the anti-proliferative eﬀect of TSA on N2A.
TSA treatment signiﬁcantly reduced the index of phosphory-
lated histone H3 (pho-H3) positive cells, a marker for cells
undergoing mitosis, and the percentage of cells that incorpo-
rate BrdU after a 2 h pulse (Fig. 3E–F and I–J). We next exam-
ined the eﬀect of Cend1 knockdown on N2A proliferation
after TSA treatment. Immunostaining for pho-H3 revealedthat the proportion of N2A cells undergoing mitosis was in-
creased by 2.3-fold in Cend1-knockdown cells as compared
to control siRNA (siCTR) transfected cells (Fig. 3G and H).
In agreement, a signiﬁcant enhancement of BrdU incorpora-
tion by 2.4-fold was observed after transfection with siCend1
as compared to siCTR (Fig. 3K and L), indicative of increased
proliferative capacity. These data suggest that Cend1 knock-
down alleviates the anti-proliferative eﬀect of TSA on N2A,
and that TSA-mediated induction of Cend1 is necessary for
executing the full anti-proliferative action of TSA. However,
there is partial rescue of proliferation, since siCend1 is not suf-
ﬁcient to restore the pho-H3 and BrdU proliferation indices to
the levels of non-TSA-treated N2A cells (Fig. 3E–L).
Fig. 2. (A–D) The Cend1 promoter is up-regulated by TSA in N2A cells. (A) Schematic representation of the Cend1-Luciferase constructs used in
this study, also showing the positions of critical Sp1 sites. (B–D) N2A cells were transiently transfected with the indicated constructs and exposed to
100 nM TSA for 24 h. *P < 0.01. (E–G) Exposure to TSA is not suﬃcient to de-repress Cend1 transcription in the non-neuronal cell lines NIH-3T3
and G774. 3T3 (E,F) and G774 (G) cells were exposed to increased doses of TSA. Total RNA was extracted and Cend1 and Gapdh mRNA levels
were examined with conventional (E) and RT-PCR assays (F,G). The Cend1 mRNA levels were normalized relative to Gapdh. In all cases
P < 0.0001.
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TSA on N2A cells. N2A eﬃciently acquire a neuronal
phenotype after exposure to TSA for 48 h as evidenced by the
outgrowth of b-III-tubulin-positive processes (Fig. 4A). Quan-
tiﬁcation of diﬀerentiation by measuring the length of b-III-
tubulin-positive processes showed a signiﬁcant induction by2.2-fold in the diﬀerentiation potential of the TSA-treated
N2A cells (Fig. 4B and C). Under these conditions, induction
of diﬀerentiation was impaired in the siCend1-transfected
N2A cells (Fig. 4D–F). Quantiﬁcation of diﬀerentiation showed
a signiﬁcant reduction by 36.2% in the diﬀerentiation potential
of the siCend1 – as compared to siCTR-treated cells (Fig. 4D
Fig. 3. Cend1 knockdown alleviates the anti-proliferative eﬀect of TSA on N2A. siRNA-knockdown of Cend1 suppresses the TSA-induced
stimulation of this gene. (A) Schematic representation of the protocol used in the siRNA experiments. N2A cells were transfected with siRNA
duplexes, and then treated with 100 nM TSA for 48 h. Cells were then either collected to extract RNA and protein or ﬁxed and immunostained for
various markers to test Cend1 protein levels, proliferation and diﬀerentiation indexes. (B) Quantiﬁcation of Cend1mRNA levels by RT-PCR analysis
as indicated. *P < 0.001. (C,D) Under the same conditions N2A cells were analyzed by western blot (C) or immunostained for Cend1 and analyzed by
confocal microscopy (D). Bar: 40 lm. (E) Mock-transfected N2A were cultured in the presence or absence of 100 nM TSA as indicated in A, and
double labeled for pho-H3 (top) and DAPI (bottom). (F) Quantiﬁcation of the data. (G) siCTR or siCend1 transfected cells were exposed to TSA as
indicated in A, and then labeled for pho-H3 and DAPI. (H) Quantiﬁcation of the data. (I) Mock-transfected cells were cultured in the presence or
absence of 100 nM TSA, pulsed for 2 h with the thymidine analog, BrdU, and double labeled for BrdU and DAPI. (J) Quantiﬁcation of the data. (K)
siCTR or siCend1 transfected cells were pulsed for 2 h with BrdU after exposure to 100 nM TSA, and then labeled for BrdU and DAPI. (L)
Quantiﬁcation of the data. *P < 0.001, **P < 0.01. Bar: 80 lm.
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Fig. 4. Cend1 knockdown impairs the TSA-induced neuronal diﬀerentiation in N2A. (A) TSA induces neuronal diﬀerentiation. Mock-transfected
N2A cells were treated as indicated in Fig. 3A, and then labeled for the neuronal marker b-III-tubulin. (B) Diﬀerentiation was quantiﬁed by
measuring the length of b-III-tubulin-positive processes, using the ImageJ software. Average process length is given in ImageJ arbitrary units. (C)
Distribution of cells according to b-III-tubulin-positive process length. (D) siCTR or siCend1 transfected cells were exposed to TSA for 48 h and then
labeled for b-III-tubulin. (E) Diﬀerentiation was quantiﬁed as shown in B. (F) Distribution of cells according to b-III-tubulin-positive process length.
*P < 0.001, **P < 0.01. Bar: 80 lm.
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illustrated by plotting the distribution of cells versus the length
of processes (Fig. 4F). Our results indicate that Cend1 induction
by TSA plays a role in the TSA-induced program of diﬀerenti-
ation in Neuro 2A cells.
Finally, we tested the involvement of Cend1 in TSA-induced
apoptosis [1]. Cend1 knockdown showed no signiﬁcant eﬀect
on apoptosis after TSA treatment of N2A, indicating that
Cend1 is not implicated in the apoptotic eﬀect of TSA on neu-
roblastoma cells (Supplementary Fig. 2).4. Discussion
Recent data suggest that HDAC enzymes are involved in the
early events of carcinogenesis, thus being potential targets for
cancer therapy. Many diﬀerent inhibitors of these enzymes
have been developed and are currently considered for thera-
peutic strategies [1,6,7]. Although HDACIs are known to
cause cell cycle arrest, diﬀerentiation and/or apoptosis, the
molecular mechanisms associated with these antitumour activ-
ities have yet to be uncovered. Here, we demonstrated that
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blastoma cells. Our results suggest that HDAC inhibition stim-
ulates Cend1 promoter activity and up-regulates Cend1 mRNA
and protein levels in N2A cells. This induction is the result of
enhanced transcriptional activation and requires de novo pro-
tein synthesis. These observations indicate that inhibition of
HDAC enzymes indirectly stimulates the expression of Cend1
through its promoter. A probable scenario is that HDACs
are not directly recruited on the Cend1 promoter, but are
responsible for suppression of another, yet unidentiﬁed, factor
that may bind to and activate the transcription of Cend1 pro-
moter after TSA action. Operation of such an indirect mecha-
nism for regulating the transcriptional repression/activation of
Cend1 in neuronal cells is further supported by the fact that
HDAC inhibition is not suﬃcient to de-repress Cend1 pro-
moter activity in non-neural cells. Thus it appears that new
protein products have to be synthesized in order to act on
and activate the Cend1 promoter in a cell type-speciﬁc manner.
In addition to the indirect eﬀect of HDACs on the Cend1
promoter, a more direct involvement on its transcriptional
suppression/activation cannot be ruled out at present evidence.
It has been previously shown that various HDACs interact
with Sp1 and are thus recruited on Sp1-dependent promoters
to suppress gene expression [18,19]. It is therefore possible that
Sp1 may contribute to Cend1 suppression. Nevertheless, the
dependence of Cend1 promoter on Sp1 for basal transcrip-
tional activity, in the absence of TSA, ([16] and Fig. 2D), indi-
cates a more general role for Sp1 in activating the Cend1
promoter. For example, Sp1 interacts directly with various
components of the TFIID complex, and activates gene tran-
scription through recruitment of the general transcription
machinery [20,21]. Taken together our data suggest that Sp1-
binding sites are required for maximal transcriptional activity,
either in the presence or absence of TSA.
HDACIs induce cell cycle arrest of N2A at the G1 phase, in-
hibit cell growth and stimulate diﬀerentiation [8]. Similarly, it
was previously shown that Cend1 expression in N2A cells is suf-
ﬁcient and necessary to induce G1 arrest via CyclinD1 down-
regulation, and up-regulation of p53, p21 and hypophosphory-
lated-pRb isoform, with a simultaneous enhancement of neuro-
nal diﬀerentiation [12,13]. Here we demonstrated that block of
Cend1 induction after HDAC inhibition alleviates the growth
arrest and diﬀerentiation-inducing phenotype that is associated
with this inhibition. These data suggest that TSA-mediated up-
regulation of Cend1 plays a role in the anti-proliferative and dif-
ferentiation-inducing eﬀect of this potential antitumour drug.
The observation that Cend1 induction byTSA is associatedwith
a concomitant p53-independent induction of p21 [17], suggests
that Cend1 may participate in both p53-dependent [13] and
independent pathways leading to cell cycle arrest. It is possible
that the levels of Cend1 may be crucial for induction of the
p53 pathway. For example, in stably transfected N2A cells
where the protein levels of Cend1 are increased by 20-fold as
compared with the parental cell line, induction of p53 is ob-
served [13]. In contrast, the smaller induction of Cend1 upon
exposure of N2A to TSA is not suﬃcient to trigger the p53 path-
way (Fig. 1). Nevertheless, Cend1 appears to be part of the net-
work of cell cycle regulators that are up-regulated by HDACIs
to achieve their antitumour eﬀect on neuroblastoma cells.More-
over, Cend1may play an essential role in coupling and synchro-
nizing these two important cellular aspects of HDACI action on
neuroblastomas.Acknowledgement: This work was supported by the GSRT EPAN
Grants YB-11 and YB-26 to RM.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2008.
01.052.
References
[1] Minucci, S. and Pelicci, P.G. (2006) Histone deacetylase inhibitors
and the promise of epigenetic (and more) treatments for cancer.
Nat. Rev. Cancer 6, 38–51.
[2] Yoshida, M., Horinouchi, S. and Beppu, T. (1995) Trichostatin A
and trapoxin: novel chemical probes for the role of histone
acetylation in chromatin structure and function. Bioessays 17,
423–430.
[3] He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell Jr., R.P.,
Rifkind, R.A., Marks, P.A., Richon, V.M. and Pandolﬁ, P.P.
(2001) Histone deacetylase inhibitors induce remission in trans-
genic models of therapy-resistant acute promyelocytic leukemia.
J. Clin. Invest. 108, 1321–1330.
[4] Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C.J., Robey,
R., Bates, S.E. and Thiele, C.J. (2002) MS-27-275, an inhibitor of
histone deacetylase, has marked in vitro and in vivo antitumor
activity against pediatric solid tumors. Cancer Res. 62, 6108–
6115.
[5] Coﬀey, D.C., Kutko, M.C., Glick, R.D., Butler, L.M., Heller, G.,
Rifkind, R.A., Marks, P.A., Richon, V.M. and La Quaglia, M.P.
(2001) The histone deacetylase inhibitor, CBHA, inhibits growth
of human neuroblastoma xenografts in vivo, alone and synergis-
tically with all-trans retinoic acid. Cancer Res. 61, 3591–3594.
[6] Johnstone, R.W. (2002) Histone-deacetylase inhibitors: novel
drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287–
299.
[7] Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T.
and Kelly, W.K. (2001) Histone deacetylases and cancer: causes
and therapies. Nat. Rev. Cancer 1, 194–202.
[8] Inokoshi, J., Katagiri, M., Arima, S., Tanaka, H., Hayashi, M.,
Kim, Y.B., Furumai, R., Yoshida, M., Horinouchi, S. and
Omura, S. (1999) Neuronal diﬀerentiation of neuro 2a cells by
inhibitors of cell cycle progression, trichostatin A and butyrolac-
tone I. Biochem. Biophys. Res. Commun. 256, 372–376.
[9] Ajamian, F., Salminen, A. and Reeben, M. (2004) Selective
regulation of class I and class II histone deacetylases expression
by inhibitors of histone deacetylases in cultured mouse neural
cells. Neurosci. Lett. 365, 64–68.
[10] Curtin, B.F., Tetz, L.M., Compton, J.R., Doctor, B.P., Gordon,
R.K. and Nambiar, M.P. (2005) Histone acetylase inhibitor
trichostatin A induces acetylcholinesterase expression and pro-
tects against organophosphate exposure. J. Cell Biochem. 96,
839–849.
[11] Koutmani, Y., Hurel, C., Patsavoudi, E., Hack, M., Gotz, M.,
Thomaidou, D. and Matsas, R. (2004) BM88 is an early marker
of proliferating precursor cells that will diﬀerentiate into the
neuronal lineage. Eur. J. Neurosci. 20, 2509–2523.
[12] Mamalaki, A., Boutou, E., Hurel, C., Patsavoudi, E., Tzartos, S.
and Matsas, R. (1995) The BM88 antigen, a novel neuron-speciﬁc
molecule, enhances the diﬀerentiation of mouse neuroblastoma
cells. J. Biol. Chem. 270, 14201–14208.
[13] Georgopoulou, N., Hurel, C., Politis, P.K., Gaitanou, M.,
Matsas, R. and Thomaidou, D. (2006) BM88 is a dual function
molecule inducing cell cycle exit and neuronal diﬀerentiation of
neuroblastoma cells via cyclin D1 down-regulation and retino-
blastoma protein hypophosphorylation. J. Biol. Chem. 281,
33606–33620.
[14] Politis, P.K., Rohrer, H. and Matsas, R. (2007) Expression
pattern of BM88 in the developing nervous system of the chick
and mouse embryo. Gene Expr. Patterns 7, 165–177.
[15] Politis, P.K., Makri, G., Thomaidou, D., Geissen, M., Rohrer, H.
and Matsas, R. (2007) BM88/CEND1 coordinates cell cycle exit
748 P.K. Politis et al. / FEBS Letters 582 (2008) 741–748and diﬀerentiation of neuronal precursors. Proc. Natl. Acad. Sci.
USA 104, 17861–17866.
[16] Papadodima, O., Sergaki, M., Hurel, C., Mamalaki, A. and
Matsas, R. (2005) Characterization of the BM88 promoter and
identiﬁcation of an 88 bp fragment suﬃcient to drive neurone-
speciﬁc expression. J. Neurochem. 95, 146–159.
[17] Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T.,
Nomura, H. and Sakai, T. (1997) Histone deacetylase inhibitor
activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Biochem. Biophys. Res. Commun. 241, 142–150.
[18] Zhang, Y. and Dufau, M.L. (2002) Silencing of transcription of
the human luteinizing hormone receptor gene by histone deace-
tylase-mSin3A complex. J. Biol. Chem. 277, 33431–33438.[19] Lagger, G., Doetzlhofer, A., Schuettengruber, B., Haidweger, E.,
Simboeck, E., Tischler, J., Chiocca, S., Suske, G., Rotheneder, H.,
Wintersberger, E. and Seiser, C. (2003) The tumor suppressor p53
and histone deacetylase 1 are antagonistic regulators of the cyclin-
dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell Biol.
23, 2669–2679.
[20] Emili, A., Greenblatt, J. and Ingles, C.J. (1994) Species-speciﬁc
interaction of the glutamine-rich activation domains of Sp1 with
the TATA box-binding protein. Mol. Cell Biol. 14, 1582–1593.
[21] Saluja, D., Vassallo, M.F. and Tanese, N. (1998) Distinct
subdomains of human TAFII130 are required for interactions
with glutamine-rich transcriptional activators. Mol. Cell Biol. 18,
5734–5743.
